I know you want faster results
By acting on central amylin receptors (particularly in the area postrema and hindbrain), cagrilintide reduces appetite and energy intake [3] [10]
No other currently licensed weight loss medication in the UK activates the glucagon receptor
and (v) adverse event reportingspecifically, that as of May 21, 2026, FDA had received more than 1,700 adverse events associated with compounded semaglutide and tirzepatide
Here is a summary of the data for Utah : Share of all patients who take a GLP-1: 0.7% Share of patients with an obesity diagnosis who take a GLP-1: 4.8% Share of male patients with an obesity diagnosis who take a GLP-1: 4.4% Share of female patients with an obesity diagnosis who take a GLP-1: 5.1% Share of GLP-1 users that are female: 60.4% For reference, here are the statistics for the entire United States: Share of all patients who take a GLP-1: 1.0% Share of patients with an obesity diagnosis who take a GLP-1: 4.8% Share of male patients with an obesity diagnosis who take a GLP-1: 4.2% Share of female patients with an obesity diagnosis who take a GLP-1: 5.2% Share of GLP-1 users that are female: 64.7% For more information, a detailed methodology, and complete results, see U.S